Hello, welcome to Bioperfectus
For A Healthier Life
Dedicated to human health with a network covering more than 50 countries and regions.
A public listed company specialized in diagnostic solution of infectious diseases and many others.
BioPerfectus, a public listed company at Shanghai Stock Exchange (SSE:688399), is one of the leading molecular diagnostic solution providers in global in-vitro diagnostic market since 2010.
One of the leading molecular diagnostic solution providers in global in-vitro diagnostic market since 2010.
Bioperfectus is key real-time PCR product supplier for Chinese disease prevention and control market.
Company news and information of Jiangsu Bioperfectus Technology Co. Ltd..
Reach out to us and explore more of bioPerfectus.
“WHO’s global hepatitis strategy aims to reduce new hepatitis infections by 90% and deaths by 65% between 2016 and 2030.
With surging cases of prevailing SARS-CoV-2 Delta variant, the testing of the variant has become a necessary and important measure to curb the further spread of the virus.
STIs is very common all over the world. More than 1 million cases of curable STIs new infected happens each day.
Copyright © 2010-2021 Jiangsu Bioperfectus Technologies Co., Ltd All Rights Reserved.